ABBV Stock: AbbVie Inc. Stock Price, Analysis & Insights
Get live abbv stock price $234.25, comprehensive AbbVie Inc. stock analysis, charts, news, and expert forecast. Real-time abbv stock data and investment insights.
Loading chart...
Company Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Company Information
- CEO
- Robert A. Michael CPA
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 55000
Contact Information
- Website
- https://www.abbvie.com
- Address
- 1 North Waukegan Road
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Market leader with 414.0 billion market capitalization
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 177.5)
✓ Lower volatility stock (Beta: 0.35) may provide portfolio stability
Business Model & Strategy
AbbVie Inc. operates in the Drug Manufacturers - General industry, focusing on medical services, pharmaceutical development, and healthcare delivery. As a large-cap company, AbbVie Inc. benefits from scale advantages, market presence, and established operations. Under the leadership of CEO Robert A. Michael CPA, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Drug Manufacturers - General model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
AbbVie Inc. competes in the Drug Manufacturers - General within the broader Healthcare. With 414.0 billion in market capitalization, the company is positioned as a market leader in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the New York Stock Exchange, AbbVie Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating AbbVie Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for AbbVie Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for large-cap equities
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for AbbVie Inc.
- ⚠Investors should consider how AbbVie Inc. fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 177.5) requires strong growth to justify
Market Cap
413.97B
P/E Ratio
177.46
Beta
0.35
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 413.97B market capitalization
- Trading Volume: 945.57K shares traded today
- Price Range: 52-week range of $163.81 - $244.81
- Exchange: Listed on New York Stock Exchange
Financial Metrics
Market Analysis for AbbVie Inc.
AbbVie Inc. (ABBV) operates in the Drug Manufacturers - General industry within the Healthcare sector. With a current market capitalization of 413.97B, the company represents a significant player in its market. The stock is currently trading at $234.25 with a positivedaily change of 0.81%.
The company's 55000 employee base and presence on the New York Stock Exchangeexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 177.46, beta of 0.35, and 52-week price range from $163.81 to $244.81when evaluating investment opportunities.
Why Invest in AbbVie Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (New York Stock Exchange)
- • Experienced leadership under Robert A. Michael CPA
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.